Research programme: orphan disease therapeutics - GlaxoSmithKline

Drug Profile

Research programme: orphan disease therapeutics - GlaxoSmithKline

Alternative Names: Rare disease therapeutics - GSK

Latest Information Update: 24 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Unspecified

Most Recent Events

  • 24 Jun 2016 Phase-I/II clinical trials in Undefined indication in United Kingdom (unspecified route) (Oxford Biomedica pipeline, June 2016)
  • 28 Oct 2015 GlaxoSmithKline in-licenses LentiVector® platform technology from Oxford BioMedica
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top